Seaport Research analyst Sonny Randhawa lowered the firm’s price target on Trulieve Cannabis (TCNNF) to $21 from $24 and keeps a Buy rating on the shares. The company has a dominant position in the Florida medical market and a strong balance sheet that should create shareholder value for years, the analyst tells investors
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCNNF:
- Trulieve Cannabis upgraded to Speculative Buy from Market Perform at Cormark
- Trulieve Cannabis Reports Strong 2024 Financial Results
- Trulieve Cannabis Reports Strong Earnings Amidst Challenges
- Trulieve Launches Onward: A Premium THC Beverage Line
- Trulieve Expands Ohio Presence with New Columbus Dispensary